Illumina, Inc. ILMN has been gaining from robust segmental growth and increased demand for its products. The company’s focus on partnerships and worldwide expansion to drive growth are expected to contribute further. However, stiff competition and a tough funding environment remain concerns.
Over the past three months, the Zacks Rank #3 (Hold) stock has outperformed its industry. The stock has gained 30.4% compared with the industry’s growth of 18.6%. Meanwhile, the S&P 500 rallied 14.4% in the same time frame.
The renowned life sciences company, which has a market capitalization of $52.93 billion, provides tools and integrated systems for analysis of genetic variation and function. The company projects 11% growth for the next five years and expects to maintain strong segmental performance. Further, it has a trailing four-quarter positive earnings surprise of 19.3%, on average.
Over the past three months, the Zacks Rank #3 (Hold) stock has outperformed its industry. The stock has gained 30.4% compared with the industry’s growth of 18.6%. Meanwhile, the S&P 500 rallied 14.4% in the same time frame.
The renowned life sciences company, which has a market capitalization of $52.93 billion, provides tools and integrated systems for analysis of genetic variation and function. The company projects 11% growth for the next five years and expects to maintain strong segmental performance. Further, it has a trailing four-quarter positive earnings surprise of 19.3%, on average.
